Articles tagged with Pancreatic Cancer
A new pilot study from University Hospitals Cleveland Medical Center found that music therapy improved pain after pancreatic surgery, supporting its feasibility and acceptability. The study also suggests continued use of music-assisted relaxation recordings over the course of hospitalization to further reduce post-operative symptoms.
SRPX2 is a multifunctional protein implicated in cancer progression, neurological disorders and fibrosis, with roles in cell proliferation, migration and angiogenesis. It also interacts with genes like FOXP2 and GRIN2A, regulating language-related synaptic plasticity and cortical development.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A new model suggests that inhibiting the cellular molecule CREB might relieve damage to the pancreas and thwart tumor development in response to alcohol. The study found that knocking out CREB relieved precancerous and cancerous lesions, even with continued alcohol exposure.
A novel cancer vaccine has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies. The vaccine targets KRAS mutations found in about 25% of solid tumors and drives about 90% of pancreatic cancers and 50% of colorectal cancers.
A retrospective cohort study found that adjuvant chemotherapy improves survival in resected early-onset pancreatic cancer patients after neoadjuvant therapy. EOPC patients showed superior survival compared to average-onset pancreatic cancer, with ACT further enhancing outcomes.
A new multi-institutional study confirmed that the NSD2 protein can be targeted with a new drug, blocking it effectively reprogrammed DNA structure, reversed and prevented cancer growth in preclinical models of KRAS-mutant lung and pancreatic cancers. Targeting the brain-liver pathway with electronic wearables could prevent cancer-asso...
The symposium will feature talks by leading researchers on various aspects of cancer, including molecular discovery, clinical application, and population impact. Key findings include the exploration of genomic inequities and their impact on cancer disparities.
Researchers have developed a novel technology that can simultaneously silence two notoriously difficult-to-target cancer-related genes, KRAS and MYC. This innovation has the potential to treat cancers that have been challenging to treat, with significant implications for patients.
A UNLV study uses an mRNA cocktail to selectively route to the pancreas, reducing the risk of immune responses and side effects. The breakthrough offers new hope for treating pancreas-related diseases, including cancer and diabetes.
Researchers developed a software fueled by genomics to predict cancer cell behavior, combining genomics technologies with computational modeling. The new 'grammar' enables communication between biology and code, allowing scientists to build digital representations of multicellular biological systems and simulate diseases like cancer.
A new case report describes the use of extracorporeal blood filtration to treat stage IV poorly differentiated pancreatic adenocarcinoma. The patient experienced clinical improvement, reduced pain, and no signs of new tumor growth over 12 months of follow-up.
Researchers at Sanford Burnham Prebys found that blocking macropinocytosis reshapes the tumor microenvironment, allowing more access to immune cells. This change made immunotherapy and chemotherapy more effective in treating PDAC tumors in mice.
Diana Hargreaves will receive $1 million to advance her project on improving immunotherapy in patients with pancreatic cancer. Her previous work identified better drug targets for cancers with SWI/SNF mutations, leading to breakthroughs in treating difficult-to-treat cancers.
Researchers at Fralin Biomedical Research Institute have identified a potential target for experimental drugs that block PRMT5, a naturally occurring enzyme some tumors rely on for survival. The study found a new drug combination that works against certain hard-to-treat cancers.
A recent national study reveals complex patterns of burden and survival trends for digestive system malignancies (DSMTs) in China. Despite progress in reducing mortality from some cancers, the overall impact remains significant, with notable disparities across demographic and geographic lines.
Early-onset gastrointestinal cancers are rising globally, particularly among younger adults. Colorectal cancer is the most common early-onset GI cancer, accounting for over half of cases, and its incidence is increasing faster than any other type of early-onset cancer.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
Researchers used AI model ChatGPT-4 to extract clinical variables from MRI and CT scans of nearly 1,000 adults with pancreatic cysts. The accuracy rate ranged from 97% for solid components to 99% for calcific lesions, comparable to human performance.
The Damon Runyon Cancer Research Foundation has awarded $4.2 million to five new Clinical Investigators conducting patient-oriented cancer research. The awards will support the development of new treatments for cancer patients, with a focus on enhancing efficacy and safety.
Researchers at Fujita Health University discovered benzaldehyde's mechanism to halt therapy-resistant pancreatic cancer growth and spread. Benzaldehyde prevents key interactions that enable cancer cells' survival and treatment resistance.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
Researchers discuss advancements in pancreatic cancer detection using biomarkers, imaging techniques, and molecular diagnostics. Novel therapies targeting the tumor microenvironment and immune evasion mechanisms are explored to improve survival outcomes.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.
A Chinese Medical Journal study investigates the role of non-coding RNAs in pancreatic cancer, revealing how dysregulation of these molecules contributes to tumor growth and treatment resistance. The research highlights potential therapeutic targets for this devastating disease.
A new study from the University of California, Davis found that switching from a high-fat to a low-fat diet slowed precancerous changes in the pancreas, even after weight gain and precancerous changes began. Researchers observed normalized gut microbiome, gene expression, and intercellular communication after dietary change.
The Phase 1 study of EBC-129 has shown encouraging signs of efficacy in heavily pre-treated pancreatic ductal adenocarcinoma patients, with an overall response rate of 25% and disease control rate of 87.5%. The drug also demonstrated a manageable safety profile, with no major treatment-related adverse events.
Scientists at UC San Francisco discovered how pancreatic cancer cells metastasize to the lungs or liver using the PCSK9 protein. PCSK9 controls cholesterol acquisition, with low levels favoring the liver and high levels supporting lung adaptation.
Researchers at Ohio State University have developed blood tests to diagnose pancreatic cancer and predict treatment outcomes. Genetic information can also help predict breast cancer survival rates, while a new blood test may improve treatment response for patients with advanced sarcoma. These findings offer promising tools for early de...
The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
The study found increasing incidence rates for five cancer types without corresponding increases in late-onset age groups. The greatest increases were seen in female breast cancer, colorectal cancer, kidney cancer, and uterine cancer.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A new study presents RMC-6236, a powerful inhibitor of RAS genes, showing promise in combination with other treatments. The study suggests that combining RMC-6236 with chemotherapy and targeted therapies could overcome therapy resistances and improve therapeutic outcomes in pancreatic cancer.
A predictive model combining tumor marker readings with patients' genetic profiles enhances predictions for patient survival and surgery decision-making. The new tool accurately identifies candidates who would benefit from surgery, suggesting that current tumor marker evaluations are inadequate for these genetic profiles.
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
A new type of connective tissue cell has been discovered that can hold back the growth of pancreatic cancer. The interferon response cancer-associated fibroblasts (ifCAF) have opposite properties to other CAF cells, which stimulate tumor development. This discovery may lead to new treatments for pancreatic cancer.
Researchers developed DNA origami structures that selectively deliver fluorescent imaging agents to pancreatic cancer cells, enabling more accurate cancer imaging and selective chemotherapy delivery. The study also explored the use of origami-folded DNA molecules loaded with chemotherapy drugs for targeted delivery to cancer cells.
Researchers at Nagoya University found that patients with high-risk stigmata and invasive nodules in their pancreatic cysts had a significant impact on their survival. The presence of invasive nodules led to improved survival rates after surgery, while those without invasive nodules had favorable outcomes even without surgery.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
A study reveals that Galectin-1 protein, located in fibroblast nuclei, promotes tumor growth and resistance to treatment. The protein regulates gene expression at a specific level, activating KRAS, a key driver of uncontrolled growth and tumor aggressiveness.
Researchers found significant disparities in quality of care and outcomes for patients with metastatic pancreatic cancer. Patients with higher social vulnerability indices were less likely to receive guideline-concordant systemic therapy, palliative care, or survive over 12 months.
Researchers have developed a new method to identify and classify pancreatic cancer cell subtypes by analyzing sugar molecules on the surface of cells. This approach may lead to more precise diagnoses and better treatment options for patients.
Researchers discovered that normal pancreatic cells can temporarily retain 'memory' of cancer-linked epigenetic marks, even in the absence of genetic mutations. This finding suggests a key role for epigenetic memory in cancer development and may explain increasing cancer rates in young people.
Researchers found that FGFR2 expression was higher in KRAS-mutated precancerous lesions and some KRAS-mutated PDAC tumors. Inactivation of FGFR2 delayed KRAS-mutated PDAC development in mice, suggesting a potential role for FGFR2 in driving cancer progression.
Scientists have found a way to effectively 'intercept' pancreatic cancer by targeting the KRAS and FGFR2 genes. This approach slows tumor formation and reduces the number of 'early versions' of cancer in the pancreas. Researchers believe this therapy could be a game-changer for patients with a family history of pancreatic cancer.
A new study led by the University of Michigan Rogel Cancer Center found that patients with three specific variants face no extra risk of dying from their cancer. The researchers used data from the Surveillance, Epidemiology and End Results programs in Georgia and California, looking at a total of about 78,000 patients with breast, colo...
Researchers found that detectable mutant KRAS circulating tumor DNA (ctDNA) indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma. The study suggests that ctDNA assays should be performed prior to treatment to have the highest yield.
Scientists have discovered a potential new treatment strategy for pancreatic cancer by identifying the molecule Neuropeptide Y (NPY) as a key driver of its spread. Blocking NPY's function has been shown to reduce cancer cell movement and metastatic outgrowth, potentially limiting disease progression.
A new type of RAS inhibitor, daraxonrasib (RMC-6236), has shown significant promise when combined with immunotherapy in preclinical models of pancreatic cancer. The study found that the treatment not only inhibited tumor growth but also reshaped the tumor microenvironment to make it more receptive to immunotherapy.
The study found that Black patients have a higher prevalence of PD-L1 overexpression, TP53 mutations, and KRASG12R mutations compared to White patients. This could affect how their cancer progresses and responds to treatment.
Excessive alcohol consumption causes severe digestive problems, including liver damage, stomach disorders, and increased cancer risk. Chronic alcohol use can lead to conditions like cirrhosis, pancreatitis, and colorectal cancer.
Researchers found that pancreatic cancer cells gain a survival edge by carrying copies of critical cancer genes on circular pieces of DNA outside chromosomes. The discovery highlights the importance of targeting extrachromosomal DNA in treating the disease.
Breast cancer death rates are predicted to increase in EU patients aged 80 years and older, while falling in all other age groups. This is attributed to a lack of regular screening and access to modern treatments.
A new study suggests that chronic stress and an unhealthy diet may work together to fuel the early development of pancreatic cancer. Researchers found that both stress-related neurotransmitters and obesity-related hormones activate a protein called CREB, which is linked to cancer cell growth.
Researchers developed a nanoparticle that delivers an mRNA vaccine targeting a KRAS antigen, boosting the immune response against pancreatic cancer. Experiments in mice showed inhibited and prevented tumor growth, as well as long-term protection against recurrence.